Triumeq® was approved by the US Food and Drug Administration (FDA) on 22nd August 2014.Triumeq, a combination of dolutegravir (integrase strand transfer inhibitor [INSTI]), abacavir, and lamivudine (both nucleoside analogue reverse transcriptase inhibitors) is indicated for the treatment of HIV-1 infection.
The European Commission (EC) has granted marketing authorisation for Triumeq® (dolutegravir/ abacavir / lamivudine) tablets on 2nd September 2014 for the treatment of HIV in adults and adolescents aged 12 years and older and weighing at least 40kg.
Regulatory applications are also being evaluated in other markets worldwide, including Australia, Brazil and Canada.
Please refer to local prescribing information for more details.
For more information for healthcare professionals, please visit our promotional website.